Protara Therapeutics, Inc. (TARA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Protara Therapeutics, Inc. (TARA) Healthcare & Pipeline Overview

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focusing on innovative treatments for cancer and rare diseases, primarily through its TARA-002 cell therapy program targeting lymphatic malformations and intravenous choline chloride for intestinal failure, positioning it within the competitive biotechnology landscape.

What Is the Investment Thesis for TARA?

Protara Therapeutics presents a focused investment opportunity within the biotechnology sector, driven by its lead asset, TARA-002, targeting lymphatic malformations. The potential success of TARA-002 in clinical trials represents a significant value driver. Further value could be unlocked through the development of intravenous choline chloride for intestinal failure associated liver disease. Key risks include clinical trial outcomes, regulatory hurdles, and the need for additional funding to support ongoing research and development. With a market capitalization of $216M and a beta of 1.50, Protara exhibits moderate volatility. Successful clinical milestones and strategic partnerships could serve as catalysts for growth, while setbacks in clinical trials or regulatory delays could negatively impact the company's valuation.

Based on FMP financials and quantitative analysis

TARA Key Highlights

Lead program TARA-002 targets lymphatic malformations, a rare disease with limited treatment options.

• Developing intravenous choline chloride for intestinal failure associated liver disease (IFALD), addressing a critical unmet need.
• Formerly ArTara Therapeutics, Inc., rebranded in May 2020 to reflect strategic focus.
• Headquartered in New York City, positioning the company within a hub of biotechnology innovation.
• Market Cap of $216M indicates the size of the company relative to its peers.

Who Are TARA's Competitors?

TARA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TARA's Key Strengths?

Promising lead program (TARA-002) targeting a rare disease.

• Development of intravenous choline chloride addressing an unmet need.
• Experienced management team.
• Focus on innovative therapies.

What Are TARA's Weaknesses?

Clinical-stage company with no currently marketed products.

• Reliance on successful clinical trial outcomes.
• Need for additional funding to support R&D.
• Small company size with limited resources.

What Could Drive TARA Stock Higher?

Phase 2 clinical trial results for TARA-002 in lymphatic malformations (expected Q4 2026).

• Regulatory submission for intravenous choline chloride (potential in 2028).
• Enrollment and progress in ongoing clinical trials.
• Potential for strategic partnerships or collaborations.

What Are the Key Risks for TARA?

Negative return on equity (-41.7%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or setbacks.
• Regulatory delays or rejections.
• Competition from other biotechnology companies.
• Need for additional funding to support R&D.
• Changes in healthcare regulations or reimbursement policies.

What Are the Growth Opportunities for TARA?

• Expansion of TARA-002 into Additional Indications: TARA-002, currently in development for lymphatic malformations, holds potential for expansion into other related indications. Exploring its efficacy in treating similar vascular anomalies could significantly broaden its market reach. The market for vascular anomaly treatments is estimated to reach $1.5 billion by 2030, presenting a substantial growth opportunity for Protara. Clinical trials for these additional indications could commence within the next 2-3 years, contingent on positive data from ongoing studies.
• Strategic Partnerships for Commercialization: Partnering with larger pharmaceutical companies for the commercialization of TARA-002 and intravenous choline chloride could accelerate market penetration and maximize revenue potential. Leveraging the established sales and marketing infrastructure of a major player could significantly enhance product uptake. Such partnerships are common in the biotechnology industry and can provide Protara with the resources and expertise needed to effectively reach patients globally. Discussions with potential partners could begin following successful Phase 2 trial results.
• Advancement of Intravenous Choline Chloride Program: The development of intravenous choline chloride for intestinal failure associated liver disease (IFALD) represents another key growth opportunity. IFALD is a serious complication of long-term parenteral nutrition, and there is a significant unmet need for effective treatments. Successful development and commercialization of this therapy could capture a substantial share of the IFALD treatment market, estimated at $500 million annually. Clinical trials are ongoing, with potential for regulatory submission within the next 3-4 years.
• Geographic Expansion into European Markets: Expanding operations into European markets represents a significant growth opportunity for Protara. The European Medicines Agency (EMA) offers a pathway for regulatory approval, and the European market for rare disease treatments is substantial. Establishing a presence in Europe could significantly increase the company's revenue and global reach. Market entry strategies could include establishing a European subsidiary or partnering with a European pharmaceutical company. Expansion efforts could commence within the next 5 years, following successful commercialization in the United States.
• Acquisition of Complementary Assets or Technologies: Protara could pursue strategic acquisitions of complementary assets or technologies to expand its pipeline and enhance its therapeutic capabilities. Acquiring companies with promising preclinical or clinical-stage assets in related therapeutic areas could accelerate the company's growth and diversify its product portfolio. Such acquisitions are common in the biotechnology industry and can provide access to new technologies and expertise. Protara could explore potential acquisition targets within the next 2-3 years, contingent on available funding and strategic alignment.

What Are TARA's Competitive Advantages?

• Proprietary cell therapy technology with TARA-002.
• Intellectual property protection through patents.
• Focus on rare diseases with limited treatment options.
• Clinical trial expertise and regulatory knowledge.

What Does TARA Do?

Protara Therapeutics, Inc., established with the mission of identifying and advancing transformative therapies, operates as a clinical-stage biopharmaceutical company. The company is dedicated to addressing unmet medical needs in the fields of cancer and rare diseases. Protara's lead program, TARA-002, is an investigational cell therapy designed for the treatment of lymphatic malformations, a rare and debilitating condition. In addition to TARA-002, Protara is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy aimed at treating intestinal failure associated liver disease (IFALD). This therapy seeks to provide a crucial nutritional component for patients suffering from this severe condition. Formerly known as ArTara Therapeutics, Inc., the company rebranded as Protara Therapeutics, Inc. in May 2020, marking a strategic shift and renewed focus on its core therapeutic programs. Headquartered in New York City, Protara Therapeutics continues to advance its clinical pipeline, striving to bring innovative solutions to patients with limited treatment options.

What Products and Services Does TARA Offer?

• Develops TARA-002, an investigational cell therapy for lymphatic malformations.
• Focuses on treatments for cancer and rare diseases.
• Creates intravenous choline chloride for intestinal failure associated liver disease.
• Conducts clinical trials to evaluate the safety and efficacy of its therapies.
• Seeks regulatory approvals from agencies like the FDA.
• Aims to address unmet medical needs in specific patient populations.
• Engages in research and development to discover new therapies.

How Does TARA Make Money?

• Develops and patents novel therapeutic candidates.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval for commercialization.
• May partner with larger pharmaceutical companies for manufacturing and distribution.

What Industry Does TARA Operate In?

Protara Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory oversight, and substantial investment in research and development. The industry is driven by the increasing demand for novel therapies to treat unmet medical needs, particularly in areas like cancer and rare diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying to develop and commercialize innovative treatments. Protara's focus on rare diseases positions it within a niche market, potentially offering opportunities for accelerated regulatory pathways and reduced competition, but also presenting challenges in terms of patient population size and market access.

Who Are TARA's Key Customers?

• Patients with lymphatic malformations.
• Patients with intestinal failure associated liver disease (IFALD).
• Healthcare providers who treat these conditions.
• Hospitals and medical centers.

Company Profile

Protara Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Jesse Shefferman. TARA has traded publicly since 2014.

Protara Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 5.66 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Protara Therapeutics, Inc. stands at -41.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.9%, the inverse of the P/E and a quick read on earnings relative to price.

TARA Valuation & Market Position

With a $216M market cap, Protara Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, TARA's quantitative score of 46/100 is below the peer average of 81/100.

Protara Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 10.1% above estimates on average.

Wall Street analysts project Protara Therapeutics, Inc. revenue of about $22.3M for fiscal 2026, with EPS near $-1.39. The estimate reflects 7 contributing analysts.

TARA Financials

TARA Latest News

No recent news available for TARA.

TARA Analyst Consensus

TARA MoonshotScore

Common Questions About TARA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources